Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Arava

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Leflunomid Testmiljö

Leflunomid

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.

  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.

  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.

  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.

  5. Brent RL. Teratogen update: Reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: Counceling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12.

  6. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.

  7. Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. Leflunomide - A human teratogen? A still not answered question An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol. 2017;71:101-107.

  8. Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis. 2018;77(4):500-509.

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.
  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.
  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.
  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.
  5. Brent RL. Teratogen update: Reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: Counceling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12.
  6. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.
  7. Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. Leflunomide - A human teratogen? A still not answered question An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol. 2017;71:101-107.
  8. Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis. 2018;77(4):500-509.